|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Irbesartan#Adult Indications and Dosage]] |
| {{Irbesartan}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Dosage and Administration==
| |
| | |
| AVAPRO may be administered with other [[antihypertensive agents]] and with or without food.
| |
| | |
| ===Hypertension===
| |
| | |
| The recommended initial dose of AVAPRO (irbesartan) is 150 mg once daily. Patients requiring further reduction in blood pressure should be titrated to 300 mg once daily.
| |
| | |
| A low dose of a [[diuretic]]may be added, if blood pressure is not controlled by AVAPRO alone. Hydrochlorothiazide has been shown to have an additive effect (seeCLINICAL PHARMACOLOGY: Clinical Studies). Patients not adequately treated by the maximum dose of 300 mg once daily are unlikely to derive additional benefit from a higher dose or twice-daily dosing.
| |
| | |
| No dosage adjustment is necessary in elderly patients, or in patients with [[hepatic impairment]] or mild to severe [[renal impairment]].
| |
| | |
| ===Nephropathy in Type 2 Diabetic Patients===
| |
| | |
| The recommended target maintenance dose is 300 mg once daily. There are no data on the clinical effects of lower doses of AVAPRO on diabetic nephropathy (seeCLINICAL PHARMACOLOGY: Clinical Studies).
| |
| | |
| ===Volume- and Salt-Depleted Patients===
| |
| | |
| A lower initial dose of AVAPRO (75 mg) is recommended in patients with depletion of intravascular volume or salt (eg, patients treated vigorously with [[diuretics]] or on [[hemodialysis]]) (see WARNINGS: Hypotension in Volume- or Salt-Depleted Patients).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = AVAPRO (IRBESARTAN) TABLET [SANOFI-AVENTIS U.S. LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7885b2a8-be4e-48ab-8113-4e6ab791eb98 | publisher = | date = | accessdate = 20 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist}}
| |
| | |
| {{Angiotensin II receptor antagonists}}
| |
| | |
| [[Category:Angiotensin II receptor antagonists]]
| |
| [[Category:Sanofi]]
| |
| [[Category:Bristol-Myers Squibb]]
| |
| [[Category:Tetrazoles]]
| |
| [[Category:Biphenyls]]
| |
| [[Category:Lactams]]
| |
| [[Category:Spiro compounds]]
| |
| [[Category:Nitrogen heterocycles]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |